Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InnoCare PharmaSHSE:688428 -7.21%74 PS Ratio is 21.43 as of Aug. 23, 2026, which is 46% above its 10-year median of 14.68. GuruFocus rates SHSE:688428 with a GF Score™ of 74/100 and a GF Value™ of ¥34.11 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 932 Biotechnology companies, InnoCare Pharma ranks better than 51.07% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, InnoCare Pharma's share price is ¥29.60.
InnoCare Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was ¥1.38. Hence, InnoCare Pharma's PS Ratio for today is 21.43.
The historical rank and industry rank for InnoCare Pharma's PS Ratio or its related term are showing as below:
SHSE:688428'
s PS Ratio Range Over the Past 10 Years
Min: 6.89 Med: 14.68 Max: 16260
Current: 9.38
During the past 9 years, InnoCare Pharma's highest PS Ratio was 16260.00. The lowest was 6.89. And the median was 14.68.
SHSE:688428's PS Ratio is ranked better than 51.07% of 932
companies
in the Biotechnology industry
Industry Median: 9.735
vs SHSE:688428: 9.38
During the past 12 months, the average Revenue per Share Growth Rate of InnoCare Pharma was 140.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 48.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 150.00% per year.
During the past 9 years, InnoCare Pharma's highest 3-Year average Revenue per Share Growth Rate was 877.80% per year. The lowest was -12.00% per year. And the median was 521.00% per year.
InnoCare Pharma (SHSE:688428) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
InnoCare Pharma PS Ratio Related Terms
InnoCare Pharma PS Ratio Historical Data
* Premium members only.
The historical data trend for InnoCare Pharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688428 vs VRTX, REGN, RVMD: PS Ratio Comparison
For the Biotechnology subindustry, InnoCare Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCare Pharma PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, InnoCare Pharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where InnoCare Pharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
InnoCare Pharma's Share Price of today is ¥29.60.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. InnoCare Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was ¥1.38.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
InnoCare Pharma (SHSE:688428) has a PS Ratio of 21.43 as of Aug. 23, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on InnoCare Pharma and its competitors. This is 46% above median its historical median of 14.68. Over the past decade, InnoCare Pharma's PS Ratio has ranged from 6.89 to 16,260.00. According to the industry distribution chart, InnoCare Pharma ranks #456 out of 932 companies in the Biotechnology industry, placing it in the top 48.9%.
Is InnoCare Pharma's PS Ratio too high?
InnoCare Pharma's current PS Ratio of 21.43 is 46% above median its 10-year median of 14.68. Over the past 10 years, this metric has ranged from a low of 6.89 to a high of 16,260.00. The Biotechnology industry median PS Ratio is 9.74. InnoCare Pharma's value of 21.43 is 120.1% above this industry median. Based on the distribution chart, InnoCare Pharma ranks #456 out of 932 companies in the Biotechnology industry, which is above the industry midpoint. Overall, InnoCare Pharma has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does InnoCare Pharma's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, InnoCare Pharma ranks #456 out of 932 companies for PS Ratio. This puts InnoCare Pharma in the upper half of its industry. The industry median PS Ratio is 9.74. InnoCare Pharma's value of 21.43 is 120.1% above this benchmark. Historically, InnoCare Pharma's own PS Ratio has ranged from 6.89 to 16,260.00 over the past decade. While the company's 10-year median is 14.68 vs. the industry median of 9.74, InnoCare Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.74, based on 932 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InnoCare Pharma's current PS Ratio of 21.43 is 120.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on InnoCare Pharma and its competitors. For the Biotechnology industry, the median PS Ratio is 9.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCare Pharma's current PS Ratio is 21.43, which is 46% above median its own 10-year median of 14.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCare Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCare Pharma (SHSE:688428) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥34.11, compared to a current price of ¥29.60 — trading 13.2% below its estimated fair value. The current PS Ratio is 21.43, which is 46% above median its 10-year median of 14.68 and 120.1% above the Biotechnology industry median of 9.74. InnoCare Pharma's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For InnoCare Pharma (SHSE:688428), the current PS Ratio is 21.43 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCare Pharma (SHSE:688428) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCare Pharma stock appears to be undervalued.
The current stock price of ¥29.60 is trading 13.2% below its estimated GF Value™ of ¥34.11.
GuruFocus considers InnoCare Pharma to be Modestly Undervalued.
Key valuation signals for SHSE:688428:
PS Ratio: 21.43 (46% above median its 10-year median of 14.68)
GF Value™: ¥34.11 vs. price of ¥29.60 (13.2% below fair value)
Industry Position: 120.1% above the Biotechnology median (#456 of 932)
No single metric tells the full story. See the SHSE:688428 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
74GF Score
Get the complete analysis for SHSE:688428
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688428 has been successfully added to your 
